[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1988

Interleukin 2 and Psoriasis

Author Affiliations

From the Surgery (Drs Lee, Lotze, Chang, and Rosenberg) and Dermatology Branches (Dr Gaspari), National Cancer Institute, National Institutes of Health, Bethesda, Md. Dr Lee is now with the Division of General Surgery, Stanford (Calif) University Hospital, Stanford University Medical Center.

Arch Dermatol. 1988;124(12):1811-1815. doi:10.1001/archderm.1988.01670120027005
Abstract

• Immunotherapy with interleukin 2 and lymphokineactivated killer cells can result in regression of metastatic cancer. Dermatologic complications associated with this therapy include erythema, pruritus, and a mild desquamation. Three patients with a history of psoriasis received high-dose interleukin 2 alone or in conjunction with lymphokine-activated killer cells for treatment of metastatic renal cell carcinoma. Two patients developed an erythrodermic exacerbation during therapy while the third patient experienced a localized flare. Topical treatment was effective in inducing remission in all three patients. Histologic analysis of serial skin biopsy specimens revealed psoriasiform changes in involved skin as well as epidermal spongiosis and a perivascular mononuclear cell infiltrate. The psoriatic exacerbation from interleukin 2 did not affect antitumor response to the therapy and should not be considered a contraindication to treatment.

(Arch Dermatol 1988;124:1811-1815)

×